# Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy

> **NCT01961349** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 279 (actual)

## Conditions studied

- Sedation to be Moderate for a Diagnostic Gastrointestinal Endoscopy and Gastrointestinal Endoscopic Polypectomy

## Interventions

- **DRUG:** Intralipid
- **DRUG:** ICI35,868 (Diprivan)
- **DRUG:** ICI35,868 (Diprivan) + EES0000645/A (SDS)

## Key facts

- **NCT ID:** NCT01961349
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-03
- **Final completion:** 2014-03
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2015-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01961349

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01961349, "Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01961349. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*